Navigation Links
Particle Sciences and SoluBest Enter into Technology Agreement
Date:10/19/2010

BETHLEHEM, Pa., Oct. 19 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement.  Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.  Particle Sciences will offer Solumer formulation and clinical trial supply manufacturing to Pharmaceutical and Biotech companies.  The patented Solumer approach utilizes GRAS polymers to create drug/polymer complexes that result in greatly improved drug solubility and bioavailability.  Once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient.  The process is easily adaptable to a wide range of molecules, making it attractive for both new chemical entities and life-cycle management challenges.

According Amir Zalcenstein, SoluBest's CEO, "We are thrilled to partner with Particle Sciences.  They are at the cutting edge of drug delivery technologies and provide us with greater access to the U.S. marketplace.  Additionally, by leveraging their significant GMP/GLP infrastructure, we are able to offer potential licensees a clear development path with a world-class CRO. Moreover, following our recent licensing deal with Dr. Reddy's, we're seeing a lot of interest in our technology, and partnering with Particle Sciences is essential in order to meet the increased demand."

Mark Mitchnick, CEO of Particle Sciences adds, "The Solumer technology fits perfectly with our growth strategy of adopting truly value added drug delivery approaches to our portfolio.  This is a proven technology that is both cost effective and scalable.  It will find application with both NCE's and generics.  Under this agreement, Particle Sciences will use Solumer technology to develop drug products for our clients.  We are very excited to be working with SoluBest and are already evaluating the technology for specific projects."

SoluBest is a clinical-stage developer of enabling drug delivery technologies, established in 2001 with the intention of developing smart polymer, self-assembling nano-particle constructs. The company is located at the Weizmann Science Park in Ness Ziona, Israel, and employs a team of experienced polymer and analytical chemists.

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with a focus on API's with difficult solubility profiles.  Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.Contact:Maureen Cochranmcochran@particlesciences.com
'/>"/>

SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
2. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
3. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
4. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
5. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
6. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
7. MicroConstants Now Offers Nanoparticle Formulation Services
8. Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities
9. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
10. Particle Sciences Expands Its Combination Product Capabilities
11. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):